A national chemical defense consortium targeting $400M–$1.2B countermeasure programs with a 3-year AI counteragent development model – BioSymetrics/Lunai Bioworks
Lunai Bioworks (NASDAQ: LNAI), through our subsidiary BioSymetrics, has launched the Pathfinder Consortium, a national academic-industry alliance designed to accelerate medical countermeasures for emerging chemical threats. #Biodefense #MedicalCountermeasures #AIforDrugDiscovery